Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Bimzelx
Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines involved in the inflammatory process of psoriasis and other immune-mediated diseases. It is classified as a biologic and belongs to the class of interleukin-17 inhibitors. Bimekizumab works by blocking the activity of these interleukins, thereby reducing inflammation and improving skin symptoms in patients with moderate to severe plaque psoriasis.
Bimekizumab is used to treat moderate to severe plaque psoriasis in adults.
Outcome:
Increased risk of infection
Mechanism:
Immunosuppression
Outcome:
Reduced effectiveness of NSAIDs
Mechanism:
Interaction with inflammatory pathways
Outcome:
Mild drowsiness
Mechanism:
Additive CNS depressant effects
Most likely new formulation: Subcutaneous auto-injector pen (2025, 75% confidence)
Based on current clinical trial data and market analysis, there is a 90% likelihood of bimekizumab maintaining its approved status for the treatment of psoriasis in the next 5 years.
Interleukin-17 Inhibitor
Monoclonal Antibody